AlphaStocks
4.4
Weak

Sarepta Therapeutics, Inc. (SRPT)

As of Sep 19, 2026, Sarepta Therapeutics, Inc. (SRPT) scores 4.4/10 on AlphaStocks' five-model composite, #128 of 168 Health Care stocks.

Health Care / Biotechnology

S&P SmallCap 600

$20.14

Below average on several measures. Research carefully.

Weak

Score based on 4 of 5 models — moderate confidence

Data as of Sep 19, 2026

#128out of 168 in Health Care

Is Sarepta Therapeutics, Inc. a Good Investment in 2026?

Sarepta Therapeutics, Inc. (SRPT) scores 4.4 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates Sarepta Therapeutics, Inc. as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -36.3% · ROC -39%. Sarepta Therapeutics, Inc. ranks #128 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-11.9Market Cap2B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -36.3% · ROC -39%

Frequently Asked Questions

Is Sarepta Therapeutics, Inc. (SRPT) a good investment?
As of Sep 19, 2026, Sarepta Therapeutics, Inc. (SRPT) scores 4.4/10 on AlphaStocks' five-model composite, #128 of 168 Health Care stocks. That score is below average, suggesting caution. Currently unprofitable — fair value estimate not available.
What is Sarepta Therapeutics, Inc.'s Piotroski F-Score?
Sarepta Therapeutics, Inc.'s Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is SRPT overvalued or undervalued?
A precise fair value estimate is not available for SRPT. Currently unprofitable — fair value estimate not available.
How does SRPT compare to other Health Care stocks?
Sarepta Therapeutics, Inc. ranks #128 out of 168 stocks in the Health Care sector, placing it in the top 76% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about SRPT?
AlphaStocks evaluates SRPT using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 4.4/10.

Similar Stocks

ABBVINCYHRMY

Compare SRPT with

ABBV vs SRPTINCY vs SRPTHRMY vs SRPT

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer